1. A randomized, double-blind, active controlled study to evaluate the safety and tolerability of ridinilazole compared with vancomycin and to assess the pharmacokinetics of ridinilazole in adolescent subjects (aged 12 to <18 years) with Clostridioides ClinicalTrials.gov identifier: NCT04802837. Updated October 13, 2022. https://ClinicalTrials.gov/show/NCT04802837. Accessed 22 Mar 2023
2. A phase 3, placebo-controlled, randomized, observer-blinded study to evaluate the efficacy, safety, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and older. ClinicalTrials.gov identifier: NCT03090191. Updated February 13, 2023. https://ClinicalTrials.gov/show/NCT03090191. Accessed 16 Mar 2023
3. ActelionLtd (2017) Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
4. Alang N, Kelly CR (2015) Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2(1):ofv004. https://doi.org/10.1093/ofid/ofv004
5. Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH (2015) SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother 70(1):182–189. https://doi.org/10.1093/jac/dku324